Eribulin mesylate



Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 1 mg per 2 mL [0.5 mg per mL])
Drug ClassMicrotubule inhibitors
Ongoing and
Completed Studies


  • Indicated for the treatment of metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
  • Indicated for the treatment of unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Latest News

loading GIF

This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Eribulin mesylate (Halaven) is recommended for treating metastatic breast cancer and unresectable or metastatic liposarcoma, especially in those who have received at least two previous chemotherapy regimens. It has demonstrated a significant increase in overall survival compared to non-eribulin treatments in both main and sensitivity analyses.
  • The analysis of Halaven's safety and effectiveness was conducted through three systematic reviews/meta-analyses, comparing it with other chemotherapy agents.
  • Regarding progression-free survival, eribulin exhibited some limitations as it showed a statistically shorter duration compared to combinations such as capecitabine and ixabepilone, or capecitabine and utidelone.
  • A notable adverse event associated with eribulin therapy is all-grade neutropenia, marking an area of concern for the drug's tolerability. Nonetheless, this toxicity profile is described as manageable.
  • For triple-negative breast cancer (TNBC), a subtype often challenging to manage, eribulin resulted in longer overall survival than capecitabine, signifying potential advantages for this particular patient group.
  • Review of real-world evidence suggests that the benefits seen in clinical trials are applicable to broader patient populations, including those with locally advanced breast cancer/metastatic disease, thereby supporting its general use beyond controlled environments.

Product Monograph / Prescribing Information

Document TitleYearSource
Halaven (eribulin mesylate) Prescribing Information.2022Eisai Inc., Nutley, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Systemic anti-cancer therapy delivery in the home: a service model. 2020British Journal of Nursing